(SECARE) Swedencare publ - Ratings and Ratios

Swedencare AB (publ) is a leading developer, manufacturer, and distributor of premium animal healthcare products, primarily catering to cats, dogs, and horses. The company operates through multiple brands, each targeting specific segments of the pet care market. Under the Healthy Breeds label, it offers a range of nutritional supplements and grooming products tailored for various pet breeds. The Innovet brand focuses on therapeutic solutions, addressing areas such as orthopedics, dermatology, and gastroenterology, among others. Stratford Animal Health provides specialized support and solutions for the veterinary community. Additionally, Swedencare markets products under other brands, including NaturVet, VETCLASSICS, NutriScience, Pet MD, VetWELL, ProDen PlaqueOff, nutravet, Animal Pharmaceuticals, Rileys Organics, and Rx Vitamins for Pets. These brands cover a wide spectrum of pet health needs, from dental care and vitamins to topical treatments and neutraceuticals. The company distributes its products through veterinarians, pet stores, and online platforms, ensuring broad accessibility. Swedencare AB (publ) was founded in 1993 and is headquartered in Malmö, Sweden.

Over the next three months, Swedencare AB (publ) is expected to experience moderate trading activity, with an average daily volume of approximately 148,053 shares. The stocks current price of 35.75 SEK is slightly below its 20-day SMA of 36.37 but remains above its 200-day SMA of 44.14, indicating a potential stabilization phase. The ATR of 1.75 suggests moderate volatility. From a fundamental perspective, the companys market cap of 5,746.28M SEK reflects its established presence in the animal healthcare sector. With a trailing P/E of 57.98 and a forward P/E of 24.04, the stock is priced at a premium, signaling market expectations for growth. The P/B ratio of 0.71 indicates that the stock may be undervalued relative to its book value, while the P/S ratio of 2.26 aligns with industry standards. The return on equity (RoE) of 1.23% suggests room for improvement in profitability. Overall, the stock is likely to remain range-bound in the near term, with potential for upward movement if the company demonstrates improved earnings or strategic growth initiatives.